Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

32.73 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
Via Benzinga
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
From Akero Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Akero Therapeutics Inc. (NASDAQ: AKRO) is a Stock Spotlight on 6/9
Via Investor Brand Network
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
From Akero Therapeutics
Via GlobeNewswire
Over $15.5M Bet On ModivCare? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed slightly higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Over $2M Bet On Akero Therapeutics? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga
Analyst Ratings for Akero Therapeutics
Via Benzinga
Analyst Expectations for Akero Therapeutics's Future
Via Benzinga
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses 
From Akero Therapeutics
Via GlobeNewswire
3 Mid Caps You Haven't Heard Of But Need To Know About
Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration. 
Via MarketBeat
Exposures Product Safety
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the Jefferies Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
$9.6M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
From Akero Therapeutics
Via GlobeNewswire
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
The battle pits 89bio and Akero in nonalcoholic steatohepatitis. 
Via Investor's Business Daily
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Akero Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
20 Favorite Biotech & Medical Stocks For 2023
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
Via Benzinga
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
From Akero Therapeutics
Via GlobeNewswire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks 
From Akero Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.